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Progress is being made in developing neuroprotective strategies for traumatic brain injuries; however, there will
never be a therapy that will fully preserve neurons that are injured from moderate to severe head injuries.
Therefore, to restore neurological function, regenerative strategies will be required. Given the limited regenerative
capacity of the resident neural precursors of the CNS, many investigators have evaluated the regenerative potential
of transplanted precursors. Unfortunately, these precursors do not thrive when engrafted without a biomaterial
scaffold. In this article we review the types of natural and synthetic materials that are being used in brain tissue
engineering applications for traumatic brain injury and stroke. We also analyze modifications of the scaffolds
including immobilizing drugs, growth factors and extracellular matrix molecules to improve CNS regeneration and
functional recovery. We conclude with a discussion of some of the challenges that remain to be solved towards
repairing and regenerating the brain.
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Tissue engineering (TE) is a relatively new and expanding
field. Using principles from material engineering and
molecular biology, tissue engineers develop organic sub-
stitutes to support or replace portions of malfunctioning
tissues or organs [1]. These substitutes are commonly
created using living cells, biomaterial scaffolding and sig-
naling molecules [2]. Studies have shown that cell replace-
ment and tissue repair is improved when engrafted cells
are delivered on a biomaterial scaffold. This is because a
scaffold can provide structural support for the cells as well
as carry necessary factors that enhance their survival and
function. TE has been investigated in a variety of organs
and is an area of active investigation for central nervous
system (CNS) repair. TE for brain injury has not been as
widely explored — likely due to the complexity of central
neural circuitry. TE has recently gained in popularity with
the realization that transplanting stem cells with a bio-
material substrate is more effective. In this article we re-
view progress to date employing TE to promote cell* Correspondence: levisosw@njms.rutgers.edu
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unless otherwise stated.replacement using neural precursors (NPs) to restore
neurological function after traumatic brain injuries and
stroke. The therapeutic value in transplanting neural pre-
cursors is extremely high due to the inability of neurons
to undergo mitosis and the incapacity of the brain to re-
pair large injuries on its own.Brain injuries
Approximately 1.7 million Americans sustain traumatic
brain injuries (TBI) each year as a result of falls, motor
vehicle accidents, being struck by objects or assaults. An
additional 800,000 individuals are affected by stroke, of
which 80% are ischemic and are of varying severity. These
numbers do not include major brain injuries caused by
infections, tumors or other CNS diseases that account for
another large population. Brain injuries are generally clas-
sified as mild, moderate or severe depending on the dam-
age sustained. The majority of TBIs are mild, resulting in
a change in mental status or state of consciousness. Severe
brain injuries may cause amnesia, long periods of uncon-
sciousness, irreversible changes in cognitive (attention and
memory), motor (coordination, balance, and limb weak-
ness/paralysis) and sensorimotor function (vision, hearing,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and personality changes) and sometimes death [3,4].
Pathophysiology
Individuals who do not die within the first few months
after sustaining a severe brain injury are often left with
disabilities and a poor prognosis for the duration of their
lives. The acute affects can be observed within the first
hours after injury and can be amplified within the first
several weeks, generally attributed to the pro-inflamma-
tory response to the injury that can last for months or
years [5]. Neuronal damage and cell loss have been exten-
sively documented and characterized in the cerebral cor-
tex, the hippocampus and the thalamus in the acute phase
following experimental brain injury [6-9]. The primary
damage created by mechanical forces at the moment of
the impact is irreversible. In response, immune cells are
recruited to the damaged site, whereupon they release
cytokines and chemokines triggering a neuroinflammatory
reaction that produces a wave of secondary cell death.
After a delay, the astrocytes surrounding the injury begin
to produce a glial scar. Once formed, this scar tissue
creates an inhibitory environment eliminating the possi-
bilities of axonal regeneration due to the formation of a
complex extracellular matrix (ECM) [10-12]. This pro-
longed and progressive pathologic cascade becomes the
basis for the deficits in cognitive and motor function that
begin in the first hours after TBI and may continue for
years.
Treatment
After a person sustains an injury, the medical team will
provide resuscitation procedures, and stabilize vital func-
tions to minimize secondary damage to the brain. Me-
chanical ventilation is used to support respiration and to
maintain lower intracranial pressure. Sensory devices may
be surgically placed into the brain cavity to monitor or
control intracranial pressure. Surgery may be required to
repair hemorrhaged arteries or to eliminate blood clots.
Blood, fluid and bone particles can be removed while
damaged tissue, blood vessels or the skull can be surgically
remodeled in severe cases where there is extensive swel-
ling. Patients are also kept sedated with medications to
prevent them from causing any additional injury and to
prevent seizures and spasticity. Doctors try to maximize
cerebral perfusion pressure and blood flow (which in-
cludes oxygen and nutrients being supplied to the brain)
while minimizing the swelling caused by pressure that
may damage more cells [13,14]. Pharmaceutical agents
also may be used to limit secondary damage to the brain
which include: diuretics to reduce edema thus decreasing
pressure; anti-seizure drugs to avoid additional brain dam-
age; and coma-inducing drugs because a comatosed brain
requires less oxygen to function [15]. Other medicationssuch as analgesics, anti-anxiety agents, anti-depressants,
anti-psychotics, muscle relaxants, sedatives and stimulants
are also commonly utilized in patients sustaining TBI [16].
To date, however, there are no therapies capable of re-
placing the neurons lost to brain injuries, thus making full
functional recovery after severe TBI impossible.
Endogenous stem cells
The brain is arguably the most difficult organ to repair
after an injury due to the complexity of network of cells
that comprise the central nervous system. Its capacity to
regenerate is complicated by the inability of neurons to
undergo mitosis. Scientists have tried to expand the
endogenous stem cells found inside the brain to repair
damage after CNS injury. Despite significant work, several
problems still exist with this approach. First, few neurons
are generated in response to injury, as the vast majority of
the new cells that are produced become glia. While infants
have significantly larger numbers of neural stem cells
(NSCs) than adults, and thus greater potential for repair
[17,18], the NSCs of the immature brain simply do not
produce many new neurons after TBI (Goodus et al.,
Submitted). Another barrier to regeneration from the
endogenous stem cells of the brain is that the pools of
NSCs are depleted with age [19].
These observations hold for several different CNS in-
jury models. Arvidsson et al. [20] researched the me-
chanisms of neuronal repair after stroke in an adult rat
model and reported that less than 1% of the destroyed
neurons are replaced from the endogenous neural pre-
cursors (NPs) of the subventricular zone (SVZ). Similar
results were obtained in rat models of stroke in the
immature animal where cell counts of immature neu-
rons vs. mature neurons revealed that greater than 75%
of the newly produced neurons failed to survive. More-
over, of those neurons that did survive, they were
predominantly GABAergic interneurons [21,22]. In a
mouse model of TBI the same pattern was seen [23].
Salman et al. [23] found that SVZ cells proximal to the
injured area produced a very small percentage of new
neurons (not quantified), while the majority became as-
trocytes. Whether the newly generated neurons died at
the injury site or failed to migrate from the SVZ to the
damaged region is unclear. However, it is known that in
the adult brain, neural progenitors have a difficult time
migrating to the injured cortex due to dense white
matter tracts [24].
Researchers are looking at pharmacological means to
generate a more robust response from SVZ precursors,
to stimulate their proliferation, increase their migration
to the affected sites and to increase their production of
region-appropriate neurons. Major advancements have
yet to be made; therefore, alternative solutions have been
sought by a number of groups.
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Given the limitations of the endogenous NSCs, transplan-
ting exogenous NPs into the injured brain has gained trac-
tion as a more appropriate solution to promote CNS
regeneration. Yet this raises the issue of which cell type to
transplant. Since brain injuries result in the demise of a
range of different neuronal cell types as well as the astro-
cytes and oligodendrocytes that support them, the ideal
cell would be one that has the capacity to produce a large
repertoire of different neurons and glia. A benefit of trans-
planting a stem cell is that a stem cell can produce a large
number of progeny that are capable of integrating into
many regions as neurons and glia to replace missing or
dysfunctional neural cells [25-28]. To date, several types
of CNS progenitors as well as several neural stem cell lines
have been transplanted into the injured brain. Cells pos-
sessing the properties of neurons have been observed,
however, it is important to note that a significant propor-
tion, regardless of the starting precursor, express the bio-
chemical and phenotypic characteristics of glia [29-38].
Both progenitor and stem cell grafts have been shown to
improve functional outcome following TBI [39-42] and in
experimental stroke [43-49]. Generally speaking, studies
that transplanted progenitors or more differentiated cells
have been less successful than studies using neural stem
cells in replacing or rebuilding a neural circuit. Although
there is no study directly comparing neuron, progenitor
and stem cell transplantations, the vast majority of re-
search on CNS regeneration focuses on the use of stem
cell or early progenitor therapies. Lineage progression
from a stem cell to a mature neuron is a process in which
proliferation, migration and multipotential capacity de-
creases. Bliss et al. [50], transplanted human post-mitotic
neurons (from hNT cell line derived from human terato-
carcinoma) into a rat model of stroke and noticed low
donor cell survival [51]. Although they saw neurite ex-
tension from hNT neurons, there was no migration.
Conversely, transplanted stem cells have shown excellent
migration to lesions even when transplanted into the
contralateral hemisphere [51-53]. Poor cell survival in the
cell preparation and during the transplantation process
has been noted, especially when transplanting more com-
mitted cells into the unwelcoming milieu of a focal neo-
cortical injury. Thus stem cell transplantation studies are
more commonly observed in CNS therapeutics, whereas
neurons and more differentiated cell types are generally
avoided. Bone marrow stromal cells have been shown to
improve outcome after brain injury and stroke [54-63],
but the evidence suggests that the functional improve-
ments obtained are not a result of cell replacement but
are due to secreted factors that are neuroprotective.
Immortalized multipotent stem cell lines, such as C17.2
(immortalized mouse neural progenitor cell line), HiB5
(rat hippocampal stem cell line) and MHP-36 (murineneural stem cell line), which display properties of stem
cells, have been successfully transplanted into rodents
subjected to either ischemic or contusive injuries [64-66].
Upon directly transplanting these cell lines each engrafted
and migrated preferentially to areas with active neurode-
generation [67-70]. HiB5 is an immortalized cell line from
embryonic day 16 rat hippocampus. Philips et al. [71]
transplanted HiB5 cells into the brain one week following
fluid percussion brain injury and reported that they re-
duced cell death in the CA3 region of the hippocampus.
MHP-36 is an immortalized mouse hippocampal neu-
roepithelial stem cell line derived from embryonic day 14
heterozygous H-2Kb-tsA58 transgenic mice (a mouse line
containing an inducible Class I antigen transgene). When
grafted into rat brains 2–3 weeks after global ischemia or
excitotoxic hippocampal injury, MHP-36 cells migrated,
improved motor and sensory function and repopulated
the lesioned CA1 hippocampal region [72-75]. Sinden
et al. and Riess et al. transplanted MHP-36 cells after
hypoxia/ischemia and fluid percussion injury respectively
[41]. Sinden observed a reduction in lesion size after
transplantation while Riess noticed a decrease in learning
deficits that correlated with the migration of MHP-36
cells to the injury site [76]. Despite these encouraging re-
sults, the MHP-36 cells cause a profound inflammatory
response [74].
Studies have also shown that these cell lines, including
the immortalized C-17.2 cell, can produce tumors when
transplanted following TBI [77]; thus, the likelihood that
immortalized stem cell lines might ever be used to treat
patients is low. Therefore, many researchers have eva-
luated grafting primary fetal and early postnatal neural
stem cells into the adult CNS to repair the brain after
injury. The rationale for using primary cells is that in the
future it may be possible to derive similar donor cells from
human embryonic stem cells (ESC) or induced pluripotent
stem cells (iPSC). Transplanting primary NPs has shown
promise as many groups have demonstrated the ability to
achieve engraftment and differentiation. Hoane et al. [78]
and Gao et al. [79] have reported differentiation of rodent
NPs into neurons, and these cells survived one year post-
transplantation into the brain. Even though a significant
improvement in cognitive recovery was not evident, the
researchers did observe greater sensorimotor recovery in
these rodents. Calcagnotto et al. [80], transplanted cells
from the mouse medial ganglionic eminences (MGE), and
demonstrated that these NPs migrated and differentiated
into cortical GABAergic interneurons. Local pyramidal
neurons were patched and electrophysiological recordings
indicated functional integration of the transplanted MGE
cells into the host tissue.
These experimental studies suggest that many obstacles
have been overcome in the grand quest to heal TBI with
exogenous cell transplants, but the extent of neuronal cell
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cells are retained [81,82]. Most of the transplanted cells
either do not survive [83-85] or differentiate into glial cells
instead of neurons [52,86-88]. This is a concern that the
stem cells transplanted do not differentiate into reactive
astrocytes that can contribute to glial scarring. Shear et al.
[87] and Boockvar et al. [52], found that NG2 positive glial
cells were produced upon transplanting NPs and Sun
et al. [88], observed that the majority of the precursors
that they transplanted became Olig2 positive cells (pre-
sumably glia). Ma et al. [86], transplanted NPs (comprised
of 4% NSCs) and reported that only 11% of the diffe-
rentiated cells expressed a neuronal marker. We have
generated data that parallel these findings, once again
obtaining poor survival of NPs when transplanted directly
into the parenchyma following TBI [89]. A new technique
or paradigm for overcoming these problems associated
with NP transplantation is necessary.
Brain tissue engineering
A focal traumatic brain injury results in a large number of
dead cells and debris that are localized near the region of
impact. Macrophages clear away the remnants of dead or
dying cells, but the injury creates a harsh, non-permissive
environment that lacks nutrients, survival factors and
most importantly, a habitable substrate and the extra-
cellular matrix (ECM) that they once resided within
[14,39,40,90]. This ECM is a scaffold that provides cells
with structural and functional support. It is comprised of
interconnected proteins and proteoglycans that create a
framework that cells adhere to. Attachment to the indi-
vidual components of this matrix transduces mechanical
signals that regulate both basic and complex cellular pro-
cesses. The proteins and proteoglycans that comprise the
ECM bind to a number of surface receptors found on cells
that can affect proliferation, migration, differentiation,
survival and other functions [91-94]. Although reactive
astrocytes produce ECM molecules in the process of ge-
nerating the glial scar, this ECM is distinctly different from
the normal ECM in the brain functionally, chemically and
mechanically [95].
Scaffolds are three-dimensional artificial structures
that are created to recapitulate the in vivo milieu provi-
ding cells with an appropriate microenvironment. Since
brain injuries vary in shape and size, scaffolds that form
after injection into the wound cavity allow for a one-
size-fits-all solution. Several factors must be considered
when creating a scaffold for a particular biological appli-
cation. In the pursuit of the ideal biomaterial design a
wish list of desirable functions can be created. The wish
list should include:
 The scaffold must be nontoxic and biocompatible
with transplantable cells. This means that thescaffold should not adversely affect cell function or
cell survival.
 The scaffold must be biocompatible with the brain
tissue environment. The scaffold should not elicit a
damaging immune response, be toxic, carcinogenic,
or adversely affect the survival of the host cells.
Upon degradation the scaffold should not generate
toxic, corrosive or acidic byproducts.
 The scaffold can maintain the “stemness” of the
transplanted cells. Indeed, because stem cells require
fewer survival factors than committed cells [96], a
transplanted stem cell, as opposed to a committed
cell or a differentiated precursor, might stand a
better chance of surviving transplantation.
Stemness can be maintained by including ligands
that will promote self-renewal and proliferation
while simultaneously decreasing differentiation.
 Biodegradation of the scaffold should be controlled.
This rate should be designed to mirror the
proliferation and growth of the transplanted cells. In
essence, as cells begin to fill the void created by an
injury, the implanted support structure should
degrade in such a fashion that it remains available
while the engrafted cells continue to grow.
Importantly, were the scaffold to remain intact it
could increase in intracranial pressure, inflammation
and fibrous encapsulation with adverse effects.
 The scaffold should be injectable. Furthermore,
brain injuries evolve and produce lesions of different
shapes and sizes. An injectable matrix will
accommodate the various types of brain defects that
need to be repaired. Instead of designing biomaterial
implants with varying shapes and sizes, only one
type of injection material would be needed (with
varying volume). Economically speaking, this would
drastically reduce manufacturing and patient costs.
 The scaffold must remain local. It is important that
the injected material, whether intact or degraded,
does not redistribute into unintended regions of the
brain or body. The scaffold should sit in, or around,
the lesion cavity until the wound has healed.
Diffusion of the scaffold itself, or the transplanted
cells into improper locations could have adverse
affects.
 The scaffold should be porous. Interconnected
pores, in the scaffold would promote blood vessel
ingrowth, nutrient flow and cellular infiltration.
Without these properties the transplanted cells may
not survive or integrate into the native tissue due to
the lack of nutrients and waste removal.
An illustration of modifications and additions made
to biomaterial scaffolds for brain TE can be seen in
Figure 1.
Figure 1 Modifications made to brain tissue engineered scaffolds to promote tissue repair. Biomaterial matrices can be designed to
incorporate cells (e.g. stem cells and progenitors), trophic and tropic factors to support exogenous or endogenous cells, factors that induce
angiogenesis, anti-inflammatory agents and synthetic adhesion molecules or extracellular matrix (ECM) derivatives.
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From this list we may narrow down the types of scaffolds
and the compositions of biomaterials optimal for use.
Since an injectable scaffold is desired, this significantly
limits the biomaterials available. Two common designs
that would apply would be hydrogel systems and micro-
or nano-particle systems. Hydrogels are liquid, but un-
dergo gelation upon injection into the brain. Often times
this is achieved through the change in temperature from
ambient air temperature of ~ 21°C to the body tempe-
rature of ~ 37°C. Alternatively, micro- or nano-particles
could be produced varying in configuration from micro-
scopic spheres, irregular particles or as fibers that are sub-
sequently suspended in a liquid or gel for transplantation.
Hydrogels
Hydrogels are water-soluble polymer chain networks.
They can absorb up to 99 percent water, which makes
them a strong candidate for brain scaffolding. They have
excellent nutrient and oxygen permeability, allowing cell
survival in the scaffold [97]. Hydrogels can also be modi-
fied with proteins, glycosaminoglycans (GAGs), cytokines,
drugs and other factors that will stimulate cell adhesion
and/or growth [98]. Cells are readily encapsulated into
hydrogels to replace missing autologous cells. Mostimportantly, hydrogels form in situ. As their name sug-
gests, they gel following injection into tissues [99]. Fur-
thermore, hydrogels possess elastic properties that are
similar to those of natural brain tissue. Hydrogels can be
created with low compressive moduli that tend to direct
stem cell differentiation toward neural lineages [100-107].
A downside to hydrogels is that cellular migration and
outgrowth is often poor due to its weak mechanical struc-
ture. In the CNS migration is essential for the initial for-
mation of cortical architectural, for axonal growth and
synaptogenesis and for white matter colonization by oligo-
dendrocyte progenitors prior to myelination. Moreover,
cells, and in particular neurons, do not extend their
neurites through three-dimensional matrices efficiently
[102,108-112]. Neurite outgrowth is best observed on 2-D
rigid structures. This is due, in part, because neuronal
growth cones require stiff substrates to pull on in order to
grow or stretch. The filopodia of many cells have similar
properties. Cells placed onto softer substrates are often
round and maintain very short processes. Thus a hydrogel
will not likely create a suitable environment for radial glial
cells (RGCs) that naturally extend their processes long
distances to the pial surface of the brain during embryonic
development. Another disadvantage in using hydrogels is
that their biodegradation is hard to control [113,114].
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tion and cytocompatibility, degradation rates are often
sacrificed or difficult to manipulate.
Microspheres and microparticles
Microspheres and microparticles on the other hand, pos-
sess a rigid surface structure, as opposed to the soft
structure of hydrogels. Due to their rigidity, the tension
that neuronal growth cones require can be created and
maintained more easily on microspheres than on hydro-
gels. Furthermore, microspheres can be transplanted by
syringe, whereupon they can mold to the injury dimen-
sions. In addition, microspheres can be fabricated to
encapsulate, immobilize and deliver specific growth or
trophic factors to aid engraftment and survival of the
transplanted cells [115]. A downside in using micro-
spheres is that they may be more difficult to inject than
hydrogels, since hydrogels are liquid within the injection
syringe and gel upon contact with the brain (usually due
to temperature differences) whereas, microparticles typi-
cally need to be suspended in an additional solution. An-
other limitation is the weak elasticity of microparticles.
Stiffness might increase neurite outgrowth, although it
might also decrease differentiation. Studies have shown
that materials constructed with elastic properties similar
to that of natural brain tissue are more likely to favor
neuronal differentiation [100,116]. Microspheres are in-
ferior in this regard.
Natural versus synthetic polymers
The material composition to be used for biomatrix con-
struction must be carefully selected. Biomaterial matrices
can be formed using natural or synthetic polymers, each
possessing unique characteristics and gelling properties
depending on fabrication. Natural polymers have many
attractive features for TE. Since these polymers are ex-
tracted from biological sources, they often resemble GAGs
found inside the human body. Furthermore, natural mole-
cules possess functional side chains that allow growth
promoting peptides, trophic factors and other bioactive
proteins to be attached. Natural materials are often
degraded safely by enzymes, whose endogenous substrates
are structurally similar. For example, the utility of chito-
san, a natural material derived from chitin (discussed in
more detail below) has been demonstrated in studies
using microcapsules containing the neurotrophic factor
NT-3. Implanting neurotrophin-containing microcapsules
increased regeneration of rat hippocampal neurons,
supporting the safety of chitosan for in vivo applications
[90]. Obstacles do exist for natural materials, including
immunogenicity, degradation rates and mechanical pro-
perties. Common natural materials used in CNS TE appli-
cations include: alginate, chitosan, collagen, gelatin and
hyaluronic acid.In contrast to natural polymers, the degradation rates
and mechanical properties of synthetic polymers are much
easier to control. Encapsulating drugs or growth factors is
also easier for synthetic material scaffolds. Unfortunately,
these polymers are rarely used in their raw form, as they
often require chemical modifications to make them bio-
compatible. For example, microspheres or rods comprised
of poly(lactic-co-glycolic acid) (PLGA) have been success-
fully transplanted into the brain within minimal side
effects. Glial infiltration was reported to be the same in
animals that received PLGA scaffolds compared to con-
trols [117-119]. There is some concern that PLGA de-
grades into acidic by-products within the brain that may
exacerbate inflammation and secondary damage after
brain injuries. Polycapralactone (PCL) or other polymers
might be a safer alternative [120], but these are not as
commonly explored as PLGA. Common synthetic mate-
rials used in CNS TE applications include poly lactic acid
(PLA), poly glycolic acid (PGA), PLGA, poly ethylene gly-
col (PEG), PCL and others.
Review
Stem cell transplantation using biomaterial scaffolds
Numerous studies have been performed in vitro to com-
pare the efficacy of scaffolds for neuronal differentiation
and survival [97,121,122] however; studies are just now
being published reporting the efficacy of stem cells trans-
planted together with a biomaterial matrix in TBI models.
Each scientific team has chosen to use a different biomate-
rial matrix. To date, scaffolds using natural and synthetic
materials constructed into rigid microparticles, rigid nano-
fibers and hydrogels have been tested. Moreover, in some
cases the scaffolds were modified by the addition of
growth factors and/or ECM molecules (Table 1).
Natural biomaterials
Tate and Shear, were some of the first investigators to use
stem cells for brain TE in models of TBI. They produced
collagen gels that contained either fibronectin and/or
laminin and showed that these scaffolds increased the sur-
vival of transplanted mouse NPs compared to NPs trans-
planted without the collagen matrix. The majority of cells
observed weeks and months later were glia and mainly
NG2+ oligodendrocyte progenitors. Tate et al. [39], ob-
tained better long-term survival of NPs when transplanted
within a supportive fibronectin and laminin matrix after
TBI than transplanted directly into the brain parenchyma.
Animals receiving these transplants also showed improved
performance in spatial learning tasks compared to injured
mice that did not receive NPs [40]. Similarly, Yu et al.
[42], transplanted E14 rat NPs within a collagen type 1
hydrogel into an adult rat model of transient cerebral
ischemic injury. Twenty-four hours after middle cerebral
artery occlusion (MCAO) the NPs were transplanted
Table 1 Brain tissue engineering studies
Author Scaffold material Cell source Injury model
Natural materials
[40] Tate et al. Collagen gel + laminin/fibronectin Mouse NPs TBI (fluid percussion)
[42] Yu et al. Collagen type 1 gel E14 Rat NPs Ischemic Stroke (MCAO)
[125] Elias et al. Collagen scaffold Adult hippocampal NPs TBI (penetrative)
[126] Jin et al. Matrigel™ Human NPs derived from ESC line Ischemic Stroke (MCAO)
[127] Liang et al. Hyaluronic acid C17.2 cell line, ReNcells, and GRPs None
[128] Wang et al. Decellularized and lyophilized Porcine
Urinary Bladder
Rat NPs TBI (CCI)
Synthetic materials
[129] Park et al. Fibrous PLGA C17.2 Ischemic Stroke (MCAO)
[130] Bible et al. ppAm-PLGA microparticles + fibronectin MHP36 cell line Transient stroke (MCAO)
[131] Cheng TY et al. RADA16-IKVAV self-assembling nanofiber Rat neuronal progenitor cell line
HCN-A94-2
Biopsy punch
Incorporation of growth factors
[161] Bible et al. PLGA + VEGF Human cell line from 12 wk. old fetus
(ReNeuron)
Ischemic Stroke (MCAO)
[170] Skop et al. Chitosan-Heparin (genipin crosslinked) +
fibronectin + FGF-2
E13.5 Rat NPs TBI (CCI)
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They reported that the collagen-NP scaffold promoted
tissue repair better than the NPs alone. Yu et al. [42], also
reported that some NPs differentiated into neurons and
formed synapses, which correlated with improvements in
functional recovery.
Elias et al. [123], used a similar approach repurposed
for TBI. They designed a collagen scaffold to deliver
adult rat hippocampal NPs in a penetrative TBI model
and delivered the NPs 1 week post-injury. When exa-
mined 4 weeks later, NPs transplanted on the scaffold
showed increased survival and migration compared to
cells injected without the scaffold; however, neuronal en-
graftment was not observed as only glial and endothelial
cells were observed amongst the grafted cells. They con-
cluded that an additional growth factor or biochemical
stimulus would be needed to achieve differentiated neu-
rons in vivo.
Jin et al. [124], used Matrigel™ to deliver NPs to treat
focal cerebral ischemia. Human NPs derived from the
ESC line BG01, were transplanted within Matrigel™ scaf-
folds into rats recovering from MCAO by electrocoagula-
tion 3 weeks prior. NPs transplanted within Matrigel™
decreased the infarct volume by 60%, which was superior
to protection obtained when only cells or only scaffolds
were injected. Moreover, cells provided with a scaffold
showed greater survival and neuronal differentiation
evidence by immunostaining and patch-clamp recordings.
Four to 9 weeks post-transplantation improvements in
sensorimotor and cognitive function were observed. Whilethese results are promising, Matrigel™ is formed from the
ECM secreted by mouse tumor cells. The specific com-
position is Matrigel™ is thus not suitable for clinical
studies.
Another popular material being explored is hyaluronic
acid, which is an abundant glycosaminoglycan in the
brain. Liang et al. [125], incorporated C17.2 cells, human
NP cells (ReNcells) and human glial restricted precursors
into a hyaluronic acid: gelatin: polyethyleneglycol dia-
crylate (2:2:1) gel. C17.2 cells were transplanted into the
brains of immune-competent rats whereas the ReNcells
and the glial precursors were transplanted into the brains
of immuno-competent mice. Survival rates for each type
of precursor cell improved when encapsulated within the
hydrogel.
In a very unique study, Wang et al. [126] cultured NPs
in a bioreactive scaffold fabricated from porcine urinary
bladders. The matrix was produced from a powder ob-
tained after de-cellularizing and lyophilizing the bladder.
De-cellularized organs (often bladders, livers and kidneys)
are rich in ECM proteins like laminin, fibronectin and col-
lagen. This powder was then rehydrated to form a hydro-
gel. Wang et al. [126] transplanted NPs into the brains of
rats recovering from severe controlled cortical impact
(CCI) injuries. This matrix supported NP proliferation
and differentiation while also reducing inflammation. Fur-
thermore, studies through 4 weeks showed improvements
in motor memory and cognition that correlated with re-
duced tissue damage, neuron loss and white matter injury.
Transplanting urinary bladder matrix alone generated
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therapy; however, only the scaffold plus NPs attenuated
memory and cognitive function.
Synthetic biomaterials
Although not as commonly employed as natural materials,
synthetic materials also have been used in brain TE appli-
cations. Park et al. [127] demonstrated greater engraft-
ment using a polymer scaffold in a stroke model. They
used a fibrous poly(glycolic acid) scaffold seeded with the
C17.2 cell line and showed that these cells could diffe-
rentiate and reduce the extent of inflammation and glial
scarring. In a more advanced study, Bible et al. [128],
produced 100–200 μm PLGA microparticles that were
plasma polymerized allylamine(ppAm) treated and coated
with fibronectin. MHP36 NPs were transplanted on these
microparticles 2 weeks after transient right MCAO. They
reported that the cells integrated effectively within the
host tissue and formed primitive neural tissue evidenced
by Sox2, NeuN and GFAP staining. Surprisingly, Bible
et al. [128] determined that transplanting MHP36 NPs
into intact tissue lead to further damage.
Some groups are encapsulating NPs into self-assem-
bling peptide hydrogels. Peptides readily self-assemble
and they can form nano-fibrous networks that mimic
native ECM. Moreover, like hydrogels they can be
injected in soluble form and subsequently solidify to
form gels in situ. Cheng et al. [129], linked the laminin
adhesion motif isoleucine-lysine-valine-alanine-valine
(IKVAV) to a self-assembling peptide AcN-RADARA
DARADARADA-CONH2 (RADA16) to form a hydrogel
that possessed a mechanical stiffness similar to brain tis-
sue. Rat NPs were encapsulated in the RADA16 –IKVAV
hydrogel and transplanted into rats recovering from a
2 mm biopsy punch-induced neocortical injury. Histo-
logical analyses revealed that the RADA16 –IKVAV gel
enhanced the survival of transplanted NPs (compared to
NPs delivered in saline), that it reduced glial scar forma-
tion and by 6 weeks post-transplantation some of the
precursors had differentiated into immature and mature
neurons evidenced by βIII-tubulin, neurofilament-H,
synapsin-1 and MAP2 immunostaining. Some of these
cells also expressed the astrocytic marker, GFAP.
Incorporating growth factors
Many of the aforementioned studies reported that cell sur-
vival was often poor and neuronal differentiation difficult
to achieve from transplanted neural stem and progenitor
cells. Therefore, investigators have found that they need to
increase the complexity of their scaffolds to incorporate
survival and/or differentiation factors. Neurotrophic fac-
tors have been incorporated into biomaterial based drug
delivery systems to promote nervous tissue repair. Nerve
growth factor (NGF) [130-136], glial cell line-derivedneurotrophic factor (GDNF) [137-142], brain derived
neurotrophic factor (BDNF) [141,143-145] and neurotro-
phin-3 (NT-3) [90,135,141,146-148] have all been added
to biomaterials to treat TBI as well as neurodegenerative
disorders spinal cord injuries and peripheral nerve in-
juries. Growth factors such as fibroblast growth factor-2
(FGF-2), epidermal growth factor (EGF), platelet-derived
growth factor (PDGF) and vascular endothelial growth
factor (VEGF) also have been used for a range of CNS dis-
orders [147-158].
In their studies, Bible et al. [159], noted that the tissue
that formed wasn’t sufficiently vascularized and hypothe-
sized that this was likely due to deficiencies in nutrients
and oxygen. Therefore, in a subsequent study they incor-
porated 0.1% (w/v) vascular endothelial growth factor
(VEGF) into the PLGA microparticles (50–100 μm) to
induce angiogenesis. When transplanted 2 weeks post-
MCAO [159], Bible et al., noticed significant endothelial
cell infiltration and neovasularization within the tissue
formed by a conditionally immortalized human NP cell
line that had been transplanted on the VEGF-PLGA mi-
croparticles into the damaged hemisphere. Microglial in-
filtration was also observed in these conditions. Although,
the VEGF promoted neurovascularizataion, neither the
survival nor the differentiation of the engrafted cells was
improved.
For the past several years we have endeavored to pro-
duce a multifunctional microsphere scaffold optimized for
transplanting NPs into the TBI brain. The scaffold that we
have fabricated is produced by electrospraying a 3% chito-
san solution into a coagulation bath to generate mi-
crospheres that range from 30-100 μm in diameter (mean:
64 μm). Similar gelation techniques have been used in
other drug delivery methods because it is a simple process
with few demerits [160-162]. Heparin, which binds FGF-2
with high affinity while retaining its biological activity, is
then covalently cross-linked to the chitosan scaffolds
using genipin (Figure 2). At 1 μg/mL approximately 80%
of the FGF-2 binds to the scaffold. The scaffold is then
further modified by coating it with fibronectin to promote
cell attachment and to increase proliferation while de-
creasing differentiation through integrin signaling path-
ways. The rationale for using FGF-2, is that this growth
factor is a known mitogen and survival factor for NPs and
it also maintains them in a primitive state and FGF-2 also
has been shown to increase the numbers of stem/progeni-
tor cells in the SVZ following TBI [163,164]. Interestingly,
soluble FGF-2 has been reported to have a half-life of
24 hours at 32°C [165] and less than 5 hours at 37°C
[166]. On the other hand, it stability increases when
affixed to heparan sulfate proteoglycans [167]. Therefore,
we predicted that immobilizing the FGF-2 to the scaffold
would increase its biological half-life. Indeed, we have
shown that fetal rat NPs plated onto a multifunctional film
Figure 2 Chitosan microsphere scaffold. Schematic representation of the formation, modification and transplantation of chitosan microspheres
for TBI repair. Chitosan is formed by electrospray technique. Heparin (red) is cross-linked to the microspheres using genipin (blue). FGF-2 (black)
selectively binds to heparin. NP cells (expressing green fluorescent protein (GFP)) are attach to the scaffold by addition of fibronectin (purple).
Spheres with cells are then transplanted subacutely into the lesion cavity following TBI.
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multipotent for at least 3 days without providing soluble
FGF-2. Moreover, they remained less mature and more
highly proliferative than cells maintained on fibronectin-
coated substrates in culture medium supplemented with
soluble FGF-2 [168,169].
When these multifunctional microspheres containing
adherent embryonic rat radial glial cells (RGCs) that ex-
pressed green fluorescent protein were injected subacutely
(7 days post injury) into the lesion cavities of adult rats
that had previously sustained CCI injuries, NPs adhered
to the microspheres could be observed 3 days after trans-
plantation surrounding the microspheres and these cells
were immunopositive for the primitive stem cell/proge-
nitor markers Nestin and BLBP. Furthermore, these trans-
planted RGCs expressed the cell proliferation marker
Ki67. At 2 weeks post-transplantation, the transplanted
cells showed a reduction in stem cell/progenitor markers
compared to 3 days, having acquired doublecortin (DCX),
Vimentin, and Oligodendrocyte Lineage Transcription
Factor 2 (Olig2), markers indicative of maturation towards
neuronal, astrocytic and oligodendrocytic lineages res-
pectively. Two weeks are still too early to expect dif-
ferentiation into fully mature neurons, astrocytes, and
oligodendrocytes and the continuous supply of FGF-2
from the scaffold will have delayed this process. Studiesexamining differentiation at 1 month post-transplantation
or longer will be necessary.
We are very encouraged by these findings as they sug-
gest that this paradigm enables balanced production of
the 3 neural cell types found in the brain, whereas most
groups [8,18,38,39] that have transplanted primary NPs
find that the majority of transplanted cells differentiate
into glial cells. Furthermore, with this approach, large
numbers of engrafted cells are observed that are repopu-
lating portions of the injury and these cells are spreading
across damaged neocortical regions with little clustering.
This is notable, as NPs transplanted without a scaffold
often remain clustered at the site of injection [89]. It is
possible that the FGF-2 that is delivered on the scaffold
is facilitating the migration of the NPs [40]. Several of
the groups listed above also have reported greater migra-
tion of transplanted NPs when delivered using a bioma-
terial scaffold.
Future directions
Significant progress has been made in neural TE, yet there
are further modifications that can be made to enhance re-
generation by combining stem cells and biomaterials. Four
major areas of concern exist: 1) achieving a high percen-
tage of cells that survive transplantation and persist after
engraftment; 2) obtaining the correct types of differentiated
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ronal subtypes and ensuring that they are positioned ap-
propriately; and 4) facilitating the integration of these new
neurons into existing circuits. Of these, the first 3 can be
addressed by improvements in neural TE.
Progress continues to be made to address the problem
of poor cell survival by modifying the biomaterial support
and new innovations are being implemented that include
altering the engrafted cells by introducing trophic factor
genes or preconditioning the cells prior to transplantation
[52]. For example, investigators have transduced NPs
using lentiviral vectors encoding the neurotrophic factors
BDNF, CNTF, GDNF, and NT-3 prior to implanting these
cells into the injured brain [170]. Genetically engineering
stem cells prior to transplantation may seem promising;
however, this manipulation will create hurdles that will
slow translation of this therapeutic approach into the
clinic. Another approach that has been used to modify the
engrafted cells is to precondition the cells. Sakata et al.
[171], preconditioned NPs with interlukin-6 (IL-6) before
transplanting them 6–7 hours after transient MCAO. The
preconditioned NPs were protected from death and they
released VEGF resulting in increased angiogenesis within
the target site.
As an alternative to pre-conditioning or genetically en-
gineering cells prior to delivery, cells can be seeded onto
scaffolds that contain components necessary to induce
these changes. Investigators are developing biomaterials
that contain immobilized plasmids that are taken up by
both the transplanted cells as well as by endogenous cells
to modify their gene expression [172-174]. With this
approach a variety of different gene products can be pro-
vided, and it is relatively simple to deliver multiple gene
products simultaneously. Incorporating plasmids into bio-
material scaffolds has been applied towards liver [175],
cartilage [176,177], bone [178-180], skin [181], vascular/
heart [182-184] and spinal cord injury [185] TE applica-
tions. Brain injuries would likely benefit from biomaterials
seeded with stem cells and loaded with plasmids that
would promote cell growth, neovascularization, and sup-
port donor cell survival until they can receive trophic sup-
port from their synaptic partners.
Investigators are also realizing that the developing brain
is generated from a variety of different NPs; therefore, they
are being more precise in matching the type of neural pre-
cursor used for engraftment. As iPSC technology becomes
more refined, investigators will be able to more accurately
control the type of NP that can be used for transplan-
tation. Controlling which cell types are produced and con-
trolling the timing of their production will require that the
local environment surrounding the engrafted cells pro-
vides them with appropriate signals. Therefore, investiga-
tors will need to establish the means to deliver relevant
growth and differentiation factors in a temporally definedsequence. This might require that peptides or plasmids
are encapsulated for slow release from the scaffold or that
they are encapsulated in a form that requires processing
to become biologically active.
Another problem that needs to be overcome is to de-
vise a strategy to regenerate a laminated brain tissue. All
of the studies to date have employed basic TE strategies
to enhance NP engraftment, survival and orchestrating a
balanced production of neuronal and glial lineages. In
order to fully repair a brain lesion, the architecture of
the regenerated neural parenchyma must recapitulate
the structure of the adjacent host tissue. This is espe-
cially true in the case of the neocortex, a region of the
brain that is frequently damaged by trauma. The neocor-
tex is a laminar tissue with 6 layers where the neurons
located within each layer have specific neurochemical
properties and they receive inputs from specific brain re-
gions. Moreover, they send their axons to other, highly
specified targets. Thus, in regenerating the neocortex,
the neurons that reside in the deeper layers of the cortex
(layers 5 and 6) cannot be located in more superficial re-
gions (layers 1 through 4), and vice versa. It has been
documented that NPs have the ability to sense their sur-
roundings and reorganize to appropriately fit a cortical
layer [186], though it is not likely that transplanted NPs
will do the same. Therefore, new biomaterial techniques
will be required to ensure the appropriate differentiation
and location of NPs within the specific brain region of
interest. For the neocortex, we can envision creating a
multilayered scaffold, in which the different biomaterial
layers govern the migration, differentiation and survival
of appropriate laminar neurons. Alternatively, it might
be possible to inject a biomaterial that would organize
into a gradient and within this gradient, plasmids, pro-
teins or other bioactive molecules would be organized to
promote the systematic migration and differentiation of
engrafted NPs [187]. Although it may be more difficult
to achieve such a highly organized structure as required
to repair neural circuits compared to other organ sys-
tems, utilizing TE applications to heal the injured brain
remains a promising discipline for future studies.
Conclusion
Over the past decade, TE strategies have been designed
and tested for brain injury repair. Studies have shown that
engraftment is improved when the stem cells are provided
functionalized biomaterial scaffolds. These biomaterial
scaffolds allow essential growth factors and other benefi-
cial molecules to be delivered resulting in improved NP
survival and repair. Even though natural materials have
been more commonly evaluated, there is little evidence
that they are superior to synthetic materials. While great
progress has been achieved, additional research is neces-
sary to determine which material(s), growth factors and/or
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determine how to best deliver them. Additional research
also is needed to match the donor cells to the region of
brain damage.
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